Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 63629-1992

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 63629-1992). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of duloxetine hydrochloride, the active ingredient in Duloxetine Delayed-Release capsules. The diagram shows the molecular arrangement including a thiophene ring, an oxygen atom connected to a naphthalene group, and an amine hydrochloride group attached to a methyl group.*

FDA Label Image

Figure 1 (Duloxetine 02)

A survival curve chart comparing the proportion of patients with relapse over time from randomization to relapse in days. The plot includes two lines, one for placebo and one for duloxetine delayed-release capsules, showing relapse proportions over a period of up to 200 days.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line graph depicting the proportion of patients with relapse over time (days) from randomization, comparing Duloxetine delayed-release capsules versus placebo. The x-axis represents time (days) up to 300, and the y-axis represents the proportion of patients with relapse, ranging from 0.0 to 1.0. The Duloxetine treatment group shows a slower increase in relapse compared to the placebo group.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine Delayed-Release capsules at 60 mg doses (BID and QD), 20 mg QD doses, and placebo. The graph shows trends for four groups, illustrating treatment effects on pain improvement.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph depicting the percentage of patients improved according to different levels of percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo. The x-axis represents percent improvement in pain from baseline, ranging from 0 to 100%. The y-axis shows the percentage of patients improved, ranging from 0 to 100%. Data points for Duloxetine groups generally show higher patient improvement percentages compared to placebo across most improvement levels.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg taken twice daily, once daily, and placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved, with lines depicting outcomes for each treatment group.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line chart depicting the percentage of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. It compares four groups: Duloxetine (DUL) 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo, showing trends of patient improvement in pain levels over varying thresholds of pain reduction.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two lines represent treatment groups: DULOXETINE HYDROCHLORIDE delayed-release capsule 60/120 mg once daily and placebo. The graph shows higher patient improvement percentages for Duloxetine across various pain improvement thresholds.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline (BOCF) for Duloxetine 60 mg once daily versus placebo. The graph shows two lines, one for Duloxetine and one for placebo, plotting patient improvement at various pain improvement percentages from greater than 0% to 100%.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline (BOCF). The graph compares two groups: placebo and Duloxetine 60/120 mg once daily. Both lines show a general decrease in patient improvement percentage as pain improvement percentage increases, with Duloxetine showing a consistently higher percentage of improvement compared to placebo.*

FDA Label Image

Label (Lbl636291992)

Label for Duloxetine Delayed-Release Capsules, USP 60 mg by Bryant Ranch Prepack. The label features the NDC 63629-1992-1, dosage strength prominently in a red box, and indicates the package contains 90 capsules. Additional storage and handling instructions are provided, along with a barcode and the BRP Pharmaceuticals logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.